BSE: 532154
JOHNSON PHARMACARE LIMITED
A BSE-listed entity classified in the services sector reported total income of Rs 158.10 lakhs against total expenses of Rs 4,304.49 lakhs in FY26, producing a net loss of Rs 5,573.39 lakhs. Revenue from operations was nil across reported quarters in FY26, and one auditor filing described the entity as an unregistered lending entity. Borrowings stood at Rs 2,140.19 lakhs in the form of inter-corporate deposits, with total assets of Rs 2,203.11 lakhs and negative other equity of Rs 5,456.48 lakhs. The statutory auditor flagged going concern doubts, non-provision of interest on loans, non-compliance with Ind AS, and investments exceeding Section 186 limits. Two directors resigned in April 2026 and were replaced by a father-son pair from Muzaffarpur, Bihar. The company lacks a Chief Financial Officer and an internal auditor, and statutory auditors resigned during the year. AR · MarketPing reader · 2026-08-02
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 3 | 3 | 0 | 0 | 0 |
| EBITDA (ex other income) | 0 | 0 | (0) | (0) | (57) |
| margin % | 4.1 | 8.8 | — | — | — |
| Owners' profit | 0 | (1) | (0) | (1) | (56) |
| EPS, as reported (₹) | 0.00 | (0.02) | 0.00 | (0.01) | (1.01) |
| ROE % · ROCE % | 0.2 · 0.2 | (2.3) · (2.2) | (0.3) · (0.3) | (1.0) · (1.0) | (12806.5) · (254.0) |
| Debt / equity (x) | 0.01 | 0.03 | 0.03 | 0.01 | 49.18 |
| Cash from operations | 2 | (12) | (0) | (2) | (58) |
| Capex | 0 | 0 | 0 | 0 | 0 |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | (0) | (0) | (0) | (1) | (0) | (0) | (0) | (56) |
| Net profit | (0) | (0) | (0) | (1) | (0) | (0) | (0) | (56) |
| EPS (₹) | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | (1.01) |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| INTL GEMOLOGICAL INST LTD | 13,326 | 21.9 | 8.96 | 12.8 | 47.8 | 58.1 | — | 64.6 |
| WEWORK INDIA MANAGEMENT L | 9,216 | 105.7 | 30.80 | 5.9 | 25.0 | 1.0 | — | 66.5 |
| NESCO LTD. | 7,252 | 17.4 | 2.42 | 12.3 | 13.8 | 14.8 | 26.2 | 68.9 |
| NIRLON LTD | 5,655 | 16.4 | 12.07 | — | 73.8 | 18.1 | — | 79.4 |
| SMARTWORKS COWORKING SP L | 5,451 | 195.5 | 10.27 | 4.6 | 2.0 | 0.3 | — | 65.8 |
| QUESS CORP LIMITED | 4,750 | 18.8 | 4.07 | 14.3 | 19.0 | 14.4 | 7.1 | 2.6 |
| INOX GREEN ENERGY SER LTD | 4,707 | 37.7 | 2.74 | 28.0 | 6.0 | 9.0 | — | 131.6 |
| INDIQUBE SPACES LIMITED | 4,091 | — | 7.95 | — | (20.7) | (2.5) | — | 67.3 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/B | 55.6 | 1.4 | 96 of 96 | 0% |
| ROCE | (255.2) | 3.4 | 102 of 103 | 1% |
| ROE | (12806.5) | 2.9 | 113 of 113 | 0% |
| Debt / Equity | 49.2 | 0.1 | 91 of 91 | 0% |
| Profit growth | (10736.0) | 5.2 | 110 of 110 | 0% |
| Market cap | 24 | 48 | 66 of 109 | 40% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 26 Sept 2026 · Trading window closed from Oct 1 till 48 hours after Q2/H1 FY27 results | compliance | minimal | — | — |
| 14 Aug 2026 · Q1 FY27 results: Johnson Pharmacare posts Rs 110 lakh loss on nil revenue | compliance | minimal | — | — |
| 13 Aug 2026 · Company confirms SEBI disclosure rule on share issues not applicable for June quarter | compliance | minimal | — | — |
| 13 Aug 2026 · Johnson Pharmacare posts Rs 110.31 lakh Q1 loss; auditor flags emphasis of matter | results | high | — | — |
| 13 Aug 2026 · Q1 FY27 results: loss widens to 110.31 lakhs; auditor flags emphasis of matter | results | high | — | — |
| 11 Aug 2026 · Board approves shift of registered office within Ahmedabad | general | low | — | — |
| 8 Aug 2026 · Board Meeting on 13 Aug to Consider Q1 FY27 Results | results | low | — | — |
| 13 Jul 2026 · Submission of Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation 2018 for the quarter ended on 30th June 2026. | compliance | minimal | — | — |
| 26 Jun 2026 · Trading window closed from July 1 until Q1 FY27 results are declared | compliance | minimal | — | — |
| 19 Jun 2026 · Johnson Pharmacare reports huge FY26 loss of Rs 55.7 cr, auditor flags going concern risk | results | high | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.